Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.44 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | CFTR | P13569 | 1/20 | 0.34 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22048471 | 0.88 | CHRM3 (0.44) | CHRM3P2RX1P2RX3P2RX4P2RX7 | |
| SCHEMBL5474669 | 0.85 | AHR (0.49) | CHRM3P2RX1P2RX3P2RX4P2RX7 | |
| SCHEMBL7317413 | 0.84 | CHRM3 (0.42) | CHRM3P2RX1P2RX3P2RX4P2RX7 | |
| SCHEMBL7322612 | 0.84 | CHRM3 (0.45) | CHRM3P2RX1P2RX3P2RX4P2RX7 | |
| SCHEMBL23028870 | 0.84 | CHRM3 (0.39) | CHRM3P2RX1P2RX3P2RX4P2RX7 | |
| SCHEMBL21645761 | 0.84 | GAA (0.49) | CHRM3P2RX4ALOX5GAACYP2C9 | |
| SCHEMBL9700918 | 0.83 | CHRM3 (0.41) | CHRM3P2RX1P2RX3P2RX4P2RX7 | |
| SCHEMBL22048472 | 0.81 | CHRM3 (0.40) | CHRM3P2RX1P2RX3P2RX4P2RX7 | |
| SCHEMBL1758787 | 0.81 | P2RX1 (0.53) | P2RX1P2RX3P2RX4P2RX7CFTR | |
| SCHEMBL11629763 | 0.80 | CHRM3 (0.39) | CHRM3P2RX1P2RX3P2RX4P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 467 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106478968-B | A kind of preparation method of nanometer of Kapton | 陕西科技大学 | 2019-06-28 | — | — | CN | claimed |
| CN-106478968-A | A kind of preparation method of nanometer of Kapton | 陕西科技大学 | 2017-03-08 | — | — | CN | claimed |
| WO-2012104262-A1 | PHOTORESPONSIVE MICROCAPSULES AND COMPOSITIONS CONTAINING SAME | UNIVERSIDAD DE SEVILLA (ES) | 2012-08-09 | — | — | WO | claimed |
| EP-2467122-A2 | PHOTORESPONSIVE SUNSCREEN COMPOSITION | Blueshift Pharma GmbH (CH) | 2012-06-27 | — | — | EP | claimed |
| US-20120148647-A1 | Photoresponsive Sunscreen Composition | BLUESHIFT PHARMA GMBH (CH) | 2012-06-14 | — | — | US | claimed |
| WO-2011020928-A2 | PHOTORESPONSIVE SUNSCREEN COMPOSITION | BLUESHIFT PHARMA GMBH (CH) | 2011-02-24 | — | — | WO | claimed |
| US-6989052-B1 | Phase change ink printing process | XEROX CORPORATION (US) | 2006-01-24 | — | — | US | claimed |
| US-20060004123-A1 | PHASE CHANGE INK PRINTING PROCESS | XEROX CORPORATION | 2006-01-05 | — | — | US | claimed |
| EP-0977769-B1 | A PROCESS FOR THE SYNTHESIS OF MODIFIED P-CHIRAL NUCLEOTIDE ANALOGUES | CT BADAN MOLEKULARNYCH IMAKROM (PL) | 2004-06-30 | — | — | EP | claimed |
| EP-1323727-A2 | Composition and methods for the synthesis of organophosphorus derivatives | GENTA INCORPORATED (US) | 2003-07-02 | — | — | EP | claimed |
| EP-0977769-A2 | A PROCESS FOR THE SYNTHESIS OF MODIFIED P-CHIRAL NUCLEOTIDE ANALOGUES | POLSKA AKADEMIA NAUK CENTRUM BADAN MOLEKULARNYCH I MAKROMOLEKULARNYCH (PL) | 2000-02-09 | — | — | EP | claimed |
| US-5936080-A | Compositions and methods for the synthesis of organophosphorus derivatives | GENTA INCORPORATED (US) | 1999-08-10 | — | — | US | claimed |
| WO-1998049179-A2 | A PROCESS FOR THE SYNTHESIS OF MODIFIED P-CHIRAL NUCLEOTIDE ANALOGUES | POLSKA AKADEMIA NAUK, CENTRUM BADAN MOLEKULARNYCH I MAKROMOLEKULARNYCH (PL) | 1998-11-05 | — | — | WO | claimed |
| EP-0828749-A4 | COMPOSITIONS AND METHODS FOR THE SYNTHESIS OF ORGANOPHOSPHORUS DERIVATIVES | GENTA INC (US) | 1998-11-04 | — | — | EP | claimed |
| US-5807837-A | ADMINISTERING TO TREAT HIV INFECTIONS TO INHIBIT THE REPLICATION OF FOREIGN NUCLEIC ACIDS IN A NORMAL CELL | SANKYO COMPANY, LIMITED (JP) | 1998-09-15 | — | — | US | claimed |
| EP-0828749-A1 | COMPOSITIONS AND METHODS FOR THE SYNTHESIS OF ORGANOPHOSPHORUS DERIVATIVES | GENTA INCORPORATED (US) | 1998-03-18 | — | — | EP | claimed |
| US-5674856-A | TREATMENT AND PROPHYLAXIS OF VIRAL INFECTIONS, INCLUDING AIDS AND TUMORS | SANKYO COMPANY, LIMITED (JP) | 1997-10-07 | — | — | US | claimed |
| EP-0611075-B1 | Modified oligodeoxyribonucleotides, their preparation and their therapeutic use | SANKYO CO (JP) | 1996-12-18 | — | — | EP | claimed |
| WO-1996037503-A1 | COMPOSITIONS AND METHODS FOR THE SYNTHESIS OF ORGANOPHOSPHORUS DERIVATIVES | GENTA INCORPORATED (US) | 1996-11-28 | — | — | WO | claimed |
| EP-0611075-A1 | Modified oligodeoxyribonucleotides, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1994-08-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120148647-A1 | Photoresponsive Sunscreen Composition | SUN2, MC1R, MITF | CHRM3 4318/4885P2RX1 608/4885P2RX3 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.